BioFactura Overview

  • Founded
  • 2004
Founded
  • Status
  • Private
  • Employees
  • 30
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $482K
Latest Deal Amount
  • Investors
  • 11

BioFactura General Information

Description

Developer of novel drugs designed to create biodefense vaccines and biological drugs against smallpox and Ebola. The company specializes in developing and manufacturing high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs using its patented StableFast Biomanufacturing Platform, enabling physicians to commercialize products to market with faster, lower cost at superior quality.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 8435 Progress Drive
  • Suite Z
  • Frederick, MD 21701
  • United States
+1 (301) 000-0000

BioFactura Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioFactura Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Grant 01-Jan-2020 $482K 00.000 Completed Generating Revenue
9. Later Stage VC (Series B) 29-Apr-2019 000 00.000 0000 Completed Generating Revenue
8. Grant 01-Jan-2018 00000 00.000 Completed Generating Revenue
7. Later Stage VC (Series A) 26-Apr-2016 00.000 00.000 00.00 Completed Generating Revenue
6. Grant 07-Apr-2016 0000 0000 Completed Generating Revenue
5. Accelerator/Incubator 04-Sep-2015 0000 Completed Generating Revenue
4. Grant 15-Sep-2014 0000 Completed Generating Revenue
3. Grant 26-Jun-2012 00.000 0000 Completed Generating Revenue
2. Accelerator/Incubator 31-Jan-2006 $25K $25K Completed Generating Revenue
1. Grant 01-Jan-2006 $3.07M Completed Generating Revenue
To view BioFactura’s complete valuation and funding history, request access »

BioFactura Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00.00 00.000
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view BioFactura’s complete cap table history, request access »

BioFactura Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel drugs designed to create biodefense vaccines and biological drugs against smallpox and Ebola. The com
Drug Discovery
Frederick, MD
30 As of 2022
00.000
0000000000 00.000

00000

modo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugi
0000 000000000
Cambridge, United Kingdom
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

00000000

mod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerci
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioFactura Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kymab Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
00000000 Formerly VC-backed Cambridge, MA 00 00000 00000000000 00000
00000 000000000000 Venture Capital-Backed Didcot, United Kingdom 0 00000 0000000000 0 00000
0000000 00000000 Formerly VC-backed Alpharetta, GA 000 00000 000000 - 000 00000
00000000 000000000 Formerly VC-backed Carmiel, Israel 000 00000 000000000 00000
You’re viewing 5 of 26 competitors. Get the full list »

BioFactura Patents

BioFactura Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2406367-A4 Separation of antigen-specific memory b cells with a conjugated biopolymer surface Granted 09-Mar-2009 000000000 0
US-20120045827-A1 Separation of antigen-specific memory b cells with a conjugated biopolymer surface Abandoned 09-Mar-2009 000000000 0
EP-2406367-A2 Separation of antigen-specific memory b cells with a conjugated biopolymer surface Granted 09-Mar-2009 000000000 0
EP-2406367-B1 Separation of antigen-specific memory b cells with a conjugated biopolymer surface Expired - Fee Related 09-Mar-2009 000000000
CA-2792709-A1 Separation of antigen-specific memory b cells with a conjugated biopolymer surface Granted 09-Mar-2009 C12M47/04
To view BioFactura’s complete patent history, request access »

BioFactura Executive Team (4)

Name Title Board Seat Contact Info
Darryl Sampey Ph.D Chief Executive Officer, President, Board Member, Chief Scientific Officer and Co-Founder
Alex DeSeabra Co-founder, Board Member & Consultant
Jeffrey Hausfeld MD Chief Medical Officer & Chairman
You’re viewing 3 of 4 executive team members. Get the full list »

BioFactura Board Members (5)

Name Representing Role Since
Alex DeSeabra BioFactura Co-founder, Board Member & Consultant 000 0000
Darryl Sampey Ph.D BioFactura Chief Executive Officer, President, Board Member, Chief Scientific Officer and Co-Founder 000 0000
Dominic Eisinger Ph.D Self Board Member 000 0000
Jeffrey Hausfeld MD BioFactura Chief Medical Officer & Chairman 000 0000
You’re viewing 4 of 5 board members. Get the full list »

BioFactura Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioFactura Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
University Of Vermont Health Network Corporation Minority 000 0000 000000 0
Wilson Sonsini Goodrich & Rosati Corporation Minority 000 0000 000000 0
Jeffrey Hausfeld Angel (individual) Minority 000 0000 000000 0
Maryland Department of Commerce Government 000 0000 000000 0
St. Louis Development Lender/Debt Provider Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »